Actinic Keratosis
Editor(s): Soyer, H.P. (Brisbane, QLD)Prow, T.W. (Brisbane, QLD)
Jemec, G.B.E. (Roskilde)
The Actinic Keratosis Virome: Can We Prevent Squamous Cell Carcinoma with a Vaccine?Frazer I.H.The University of Queensland Diamantina Institute, Brisbane, Qld., Australia
|
|
Soyer HP, Prow TW, Jemec GBE (eds): Actinic Keratosis. Curr Probl Dermatol. Basel, Karger, 2015, vol 46, pp 28-35
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Published online: December 18, 2014
Cover Date: 2015
Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0
ISBN: 978-3-318-02762-4 (Print)
eISBN: 978-3-318-02763-1 (Online)
Abstract
Squamous skin cancer, which is commonly called squamous cell carcinoma (SCC), represents an immunological puzzle. The major skin cancers (SCC, basal cell carcinoma, Merkel cell carcinoma, and melanoma) and actinic keratosis (AK), as a potential precursor lesion of SCC, are common in immune-suppressed patients. The increased risk of a particular cancer in chronically immune-suppressed patients is a feature of those cancers for which a virus contributes to the aetiology. However, amongst the skin cancers mentioned, a causal virus (Merkel polyomavirus) has been identified only for Merkel tumours. It is therefore reasonable to determine whether a virus or viruses contribute to the risk of the development of AK and SCC. This chapter will first consider the limitations of the methodologies available for determining the roles of viruses in the aetiologies of AK and SCC and review current evidence of the contribution of a virus to the risk of developing these diseases. It will then consider why there might be an increased risk of AK in chronically immune-suppressed patients although no relevant virus can be identified.
© 2015 S. Karger AG, Basel
Related Articles:
References
- Piselli P, Busnach G, Fratino L, Citterio F, Ettorre GM, De Paoli P, et al: De novo malignancies after organ transplantation: focus on viral infections. Curr Mol Med 2013;13:1217-1227.
- Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-3044.
- Zhang X, Zhang Z, Zheng B, He Z, Winberg G, Ernberg I: An update on viral association of human cancers. Arch Virol 2013;158:1433-1443.
- Saveria Campo M, Moar MH, Jarrett WF, Laird HM: A new papillomavirus associated with alimentary cancer in cattle. Nature 1980;286:180-182.
- Weissenborn S, Neale RE, Waterboer T, Abeni D, Bavinck JN, Green AC, et al: Beta-papillomavirus DNA loads in hair follicles of immunocompetent people and organ transplant recipients. Med Microbiol Immunol 2012;201:117-125.
- Mullins CS, Linnebacher M: Human endogenous retroviruses and cancer: causality and therapeutic possibilities. World J Gastroenterol 2012;18:6027-6035.
- Halliday GM, Agar NS, Barnetson RS, Ananthaswamy HN, Jones AM: UV-A fingerprint mutations in human skin cancer. Photochem Photobiol 2005;81:3-8.
- Bernard HU, Burk RD, Chen Z, Van DK, Hausen H, de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-79.
- Pfister H: Chapter 8: human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003;(31):52-56.
- Neale RE, Weissenborn S, Abeni D, Bavinck JN, Euvrard S, Feltkamp MC, et al: Human papillomavirus load in eyebrow hair follicles and risk of cutaneous squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2013;22:719-727.
- McCance DJ, Kopan R, Fuchs E, Laimins LA: Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci U S A 1988;85:7169-7173.
- Munoz N: Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000;19:1-5.
- Bosch FX, de Sanjose S: Human papillomavirus in cervical cancer. Curr Oncol Rep 2002;4:175-183.
- Joseph AW, D'Souza G: Epidemiology of human papillomavirus-related head and neck cancer. Otolaryngol Clin North Am 2012;45:739-764.
- Barbosa MS, Edmonds C, Fisher C, Schiller JT, Lowy DR, Vousden KH: The region of the HPV E7 oncoprotein homologous to adenovirus E1a and SV40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J 1990;9:153-160.
- Mietz JA, Unger T, Huibregtse JM, Howley PM: The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBO J 1992;11:5013-5020.
- Orth G, Jablonska S, Favre M, Croissant O: Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. Proc Natl Acad Sci U S A 1978;75:1537-1541.
- Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M: Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002;32:579-581.
- Bunney MH, Barr BB, McLaren K, Smith IW, Benton EC, Anderton JL, et al: Human papillomavirus type 5 and skin cancer in renal allograft recipients. Lancet 1987;2:151-152.
- Christoph T, Muller-Rover S, Audring H, Tobin DJ, Hermes B, Cotsarelis G, et al: The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol 2000;142:862-873.
- Asgari MM, Kiviat NB, Critchlow CW, Stern JE, Argenyi ZB, Raugi GJ, et al: Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 2008;128:1409-1417.
- Plasmeijer EI, Neale RE, de Koning MN, Quint WG, McBride P, Feltkamp MC, et al: Persistence of betapapillomavirus infections as a risk factor for actinic keratoses, precursor to cutaneous squamous cell carcinoma. Cancer Res 2009;69:8926-8931.
- Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL: Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol 2011;131:1745-1753.
- Ganzenmueller T, Yakushko Y, Kluba J, Henke-Gendo C, Gutzmer R, Schulz TF: Next-generation sequencing fails to identify human virus sequences in cutaneous squamous cell carcinoma. Int J Cancer 2012;131:E1173-E1179.
- Proby CM, Harwood CA, Neale RE, Green AC, Euvrard S, Naldi L, et al: A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant 2011;11:1498-1508.
- Bouwes Bavinck JN, Neale RE, Abeni D, Euvrard S, Green AC, Harwood CA, et al: Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 2010;70:9777-9786.
- Andersson K, Waterboer T, Kirnbauer R, Slupetzky K, Iftner T, de Villiers EM, et al: Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev 2008;17:189-195.
- Jarrett WF, Campo MS, Blaxter ML, O'Neil BW, Laird HM, Moar MH, et al: Alimentary fibropapilloma in cattle: a spontaneous tumor, nonpermissive for papillomavirus replication. J Natl Cancer Inst 1984;73:499-504.
- Tan MJ, White EA, Sowa ME, Harper JW, Aster JC, Howley PM: Cutaneous beta-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling. Proc Natl Acad Sci USA 2012;109:E1473-E1480.
- Sperling T, Oldak M, Walch-Ruckheim B, Wickenhauser C, Doorbar J, Pfister H, et al: Human papillomavirus type 8 interferes with a novel C/EBPbeta-mediated mechanism of keratinocyte CCL20 chemokine expression and Langerhans cell migration. PLoS Pathog 2012;8:e1002833.
- Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR: Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev 2011;239:85-98.
- Mittal D, Kassianos AJ, Tran LS, Bergot AS, Gosmann C, Hofmann J, et al: Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein E7. J Invest Dermatol 2013;133:2686-2694.
- Mattarollo SR, Yong M, Gosmann C, Choyce A, Chan D, Leggatt GR, et al: NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins. J Immunol 2011;187:1601-1608.
- Feng H, Shuda M, Chang Y, Moore PS: Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096-1100.
- Harms PW, Patel RM, Verhaegen ME, Giordano TJ, Nash KT, Johnson CN, et al: Distinct gene expression profiles of viral- and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis. J Invest Dermatol 2013;133:936-945.
- Cheng J, Rozenblatt-Rosen O, Paulson KG, Nghiem P, DeCaprio JA: Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. J Virol 2013;87:6118-6126.
- Gomez BP, Wang C, Viscidi RP, Peng S, He L, Wu TC, et al: Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen. Cell Biosci 2012;2:36.
- Ehlers B, Wieland U: The novel human polyomaviruses HPyV6, 7, 9 and beyond. APMIS 2013;121:783-795.
- Panagiotakis GI, Papadogianni D, Chatziioannou MN, Lasithiotaki I, Delakas D, Spandidos DA: Association of human herpes, papilloma and polyoma virus families with bladder cancer. Tumour Biol 2013;34:71-79.
- Roberts IS, Besarani D, Mason P, Turner G, Friend PJ, Newton R: Polyoma virus infection and urothelial carcinoma of the bladder following renal transplantation. Br J Cancer 2008;99:1383-1386.
- Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB: Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe 2010;7:509-515.
- Moens U, Ludvigsen M, Van Ghelue M: Human polyomaviruses in skin diseases. Patholog Res Int 2011;2011:123491.
- Pastrana DV, FitzGerald PC, Phan GQ, Raiji MT, Murphy PM, McDermott DH, et al: A divergent variant of the eleventh human polyomavirus species, Saint Louis polyomavirus. Genome Announc 2013;1:e00812-13.
- Varmus H: Retroviruses. Science 1988;240:1427-1435.
- Francis DP, Essex M: Leukemia and lymphoma: infrequent manifestations of common viral infections? A review. J Infect Dis 1978;138:916-923.
- Hohn O, Hanke K, Bannert N: HERV-K(HML-2), the best preserved family of HERVs: endogenization, expression, and implications in health and disease. Front Oncol 2013;3:246.
- Katoh I, Kurata SI: Association of endogenous retroviruses and long terminal repeats with human disorders. Front Oncol 2013;3:234.
- Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A: The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013;169:502-518.
- Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PC, et al: Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007;157(suppl 2):25-31.
- Tanaka N, Ohata C, Ishii N, Imamura K, Ueda A, Furumura M, et al: Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients. J Dermatol 2013;40:962-967.
- Gupta AK, Paquet M, Villanueva E, Brintnell W: Interventions for actinic keratoses. Cochrane Database Syst Rev 2012;12:CD004415.
- Hannigan GD, Grice EA: Microbial ecology of the skin in the era of metagenomics and molecular microbiology. Cold Spring Harb Perspect Med 2013;3:a015362.
Article / Publication Details
First-Page Preview
Published online: December 18, 2014
Cover Date: 2015
Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 0
ISBN: 978-3-318-02762-4 (Print)
eISBN: 978-3-318-02763-1 (Online)
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
